News 
Market Data 
Discover
Zephyr
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Multiple rounds! lol! 
)))) Z
I've been flipping it...bought 5000 again this morning at .305 (filled 4800 and two 100 trades) trying to sell at .385. When that's done that will be the 4th flip. Z
sweeeeeet! )) Z eom
getting? U R dizzy. Z
CHTR another weeee! 
Have a good time Buzz 
actually glad I didn't get filled....hate to hold a flip overnight. We'll see what tomorrow brings
Z
that's me... Richer Chicken Shit! lol! ) eom Z
out of aagh at .21 ))) eom
lol! He's really not all that....only most.
JK!
Z
this is the part where I see a little weakness in their report...I'd have thought that with the growth in revenue that this would have been no problem getting that funding...imho. But I shit about this stuff.
We are in the process of seeking additional financing to forward our business plan, but have not entered into any agreements to obtain such financing. There is no assurance that such financing will be available, or if available, that such financing will be available on reasonable terms. Even if we do obtain such financing, there is no assurance that we will be able to generate profitable operations.
Because we have not yet raised the funding management believes is required to rollout our complete business plan, we have taken, and are continuing to take, steps to reduce our operating costs. We have decided to move a significant portion of our U.S. operations to China where we can benefit from lower overhead costs and further capitalize on the growth potential and success we have already experienced in our Media and Advertising business in Hong Kong and China. Some management and marketing operations will remain in the U.S. In addition, we have suspended operations and development of our consumer portals, RateandSave and More2Save, in our Media and Advertising division.
DATA weeeeee!
Multi-Billion Dollar North American Pharmaceutical Company Becomes the Fourth Client in 2006 Choosing to Standardize on the DATATRAK eClinical(TM) Unified Platform
PR Newswire - August 14, 2006 7:30 AM ET
Related Quotes
Symbol Last Chg
DATA Trade 6.40 +0.45
Real time quote.
DATATRAK International, Inc. (Nasdaq: DATA), a technology company focused on global eClinical solutions for the clinical trials industry, today reported that its unified platform has been selected by a multi-billion dollar North American clinical trial sponsor with the objective of standardizing their international product development efforts on this single architecture. This relationship represents another new client for DATATRAK and is the fourth customer in 2006 that has decided to exclusively deploy the Company's product suite for an entire multi-year pipeline of clinical trials. The selection of DATATRAK eClinical(TM) was made following an extensive evaluation of the world's leading clinical trial technology providers which lasted several months and culminated in a detailed technology audit of DATATRAK's capabilities and compliance with regulatory guidelines.
Work on the first 8 projects is to begin in 2006. This group of trials together with process consulting by DATATRAK has a combined initial budgetary value estimated to exceed $1 million. This client has also stated goals of initiating a large number of additional clinical trials during 2007 and beyond, some of which represent larger-sized projects. The expected number and budgetary estimates of the additional trials will be finalized in the coming quarters, at which time, more details will be provided. A Master Agreement is currently being finalized by both parties that will serve as the template for all future statements of work for individual clinical trial awards.
As another positive sign of the existence of a long-term commitment and working relationship with DATATRAK, this sponsor has stated a willingness to employ DATATRAK's consulting capabilities with its eMerge Program in order to design the proper workflows and Standard Operating Procedures for a complete eClinical trial program. DATATRAK is also working closely with the sponsor on the most efficient processes and workflows that can be used with Contract Research Organizations (CROs) that the sponsor may select to provide additional services in conjunction with eClinical deployments as part of their clinical trial programs.
DATATRAK eClinical(TM) was chosen because of its unique position in the market of having the broadest and the most unified platform of capabilities existing under one software architecture obviating the need for expensive and risky integration procedures involved with databases residing in unrelated applications. It represents the only clinical trial technology that can collectively house information obtained from electronic case report forms, electrocardiographic- and/or image-generated media associated with increasingly important cardiac safety initiatives and also can facilitate critically important and timely workflow priorities under one interrelated platform.
"We are very pleased to add the fourth customer to a growing list of companies that have selected DATATRAK eClinical(TM) as their platform for all future clinical trials," stated Dr. Jeffrey A. Green, President and Chief Executive Officer of DATATRAK International, Inc. "This is the type of market maturation that we highlighted in our recent conference call whereby clients are implementing blocks of clinical trials at a time from their pipeline. Such a process saves in repetitive contracting efforts and likely contributes to enhanced development productivity, but only occurs when a single standard platform is chosen rather than bouncing from vendor to vendor. This client is especially significant because of their size and the fact that they view DATATRAK as a service provider with an enterprise information platform that is capable of fulfilling their blueprints for growth. The ability to unify all clinical trial data is without a doubt the main reason for these commitments. This client adds to our already firm foundation for achieving our stated goals over the next several years of having four to five anchor clients that are capable of initiating 30-40 new clinical trials each year with DATATRAK eClinical(TM)."
DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Technology Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 56 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 separate drugs that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, Bonn, Germany, and Bryan, Texas. Its common stock is listed on the NASDAQ stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at http://www.datatrak.net .
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. Factors that may cause actual results to differ materially from those in the forward- looking statements include the ability of the Company to absorb corporate overhead and other fixed costs in order to successfully market its software; the development and fluctuations in the market for clinical trial technology; the degree of the Company's success in obtaining new contracts; the timing of payments from customers and the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; governmental regulation; the early stage of the Company's business and operations; and general economic conditions. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry.
SOURCE DATATRAK International, Inc.
Jeffrey A. Green, Pharm.D., FCP, President and Chief Executive Officer,
+1-440-443-0082 ext. 112, or Terry C. Black, Chief Financial Officer, +1-440-443-0082
ext. 110, both of DATATRAK International, Inc.; or Investor Relations, Neal Feagans
of Feagans Consulting, Inc for DATATRAK International, Inc., +1-303-449-1184
http://www.prnewswire.com
sweet...back in at .20 C what happens... Z
PACT weeee! ...UPDATE 1-TABLE-PacificNet Q2 earnings rise; sets Q3, 2006 view
August 14, 2006 08:38:17 (ET)
(Adds Q3, 2006 outlook, share movement)
Aug 14 (Reuters) -
PACIFICNET INC. (PACT,Trade)
Latest Forecast* No. of Yr ago
analysts qtr EPS (diluted, $/shr) 0.08 -- -- 0.06 Net^ ($ thousands) 952 -- -- 593 Revenue ($ million) 19.3 14.5 1 12.3
*Source: Reuters Estimates
^Available to common stockholders
--The company said its second-quarter net profit was partly offset by increased expenses of $500,000 due to added management expense, increased audit fees, and increased interest expense of $100,000 due to its recent convertible debenture.
--For the latest quarter, one analyst had expected the company to earn 10 cents a share, before special items, according to Reuters Estimates.
--For the third quarter, the call center and customer relationship management services provider forecast net income of between $900,000 and $1 million, or about 9 cents to 10 cents per basic share, on total revenue of $20 million to $21 million.
--One analyst expects third-quarter earnings of 11 cents a share, before exceptional items, on revenue of $16.4 million, according to Reuters Estimates.
--The company reiterated its fiscal 2006 earnings outlook of about 39 cents to 43 cents per basic share, on total revenue of between $74 million and $77 million.
--For fiscal 2006, two analysts on average expect the company to earn 43 cents a share, before special items, while the revenue view of one analyst is $65.2 million, according to Reuters Estimates.
--Shares of the company rose about 9.6 percent to $5.59 in morning trade on the Nasdaq. (Reporting by Satrajit Majumder and Aditi Samajpati in Bangalore)
Happy Birthday! That's the way to filp it and then hold free shares! It may spike....I may buy again also.... I'm watching.
HDSN down a bunch...
Maybe time to start buy again....hmmmmmmm?
Z
out of aagh...sweet one...thanks timing. )) eom
TRPH - nice dip in at .13....
AI
